Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Multiple-Center, Double-Blind, Placebo-Controlled Study of the Safety and Analgesic Efficacy of Repeated Dosing of PMI-150 (Intranasal Ketamine) to Treat Acute Post-Operative Pain Following Orthopedic Trauma, Injury, or Surgery.

Next Previous
Search
Trial Profile

Randomized, Multiple-Center, Double-Blind, Placebo-Controlled Study of the Safety and Analgesic Efficacy of Repeated Dosing of PMI-150 (Intranasal Ketamine) to Treat Acute Post-Operative Pain Following Orthopedic Trauma, Injury, or Surgery.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ketamine (Primary)
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Hospira; Javelin Pharmaceuticals

Most Recent Events

  • 10 Jan 2012 Actual end date changed from Feb 2009 to Aug 2011 as reported by ClinicalTrials.gov.
  • 12 Feb 2010 Primary endpoint 'Sum of pain intensity difference' has been met, after reexamination of topline data by third party.
  • 12 Aug 2009 Primary endpoint 'Sum of pain intensity difference' has not been met.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top